Sanofi SAN.PA · EUR
Health Care · Pharmaceuticals · Euronext Paris · 🇫🇷 France
Euro Stoxx 50
85.76
+2.41%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sanofi
Its shares trade on Euronext Paris under the ticker SAN.PA. It has been listed since 1 July 2002. It is a member of the Euro Stoxx 50. In the fiscal year to 31 December 2025, it reported revenue of €46.72bn and net income of €7.81bn. At that date it held total assets of €126.81bn and shareholders' equity of €71.38bn.
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jul 2002
- Employees
- 99,412
- Website
- sanofi.com ↗
Leadership
Pay as last reported
- Mr. Frederic OudeaIndependent Chairman of the Board€884,836
- Mr. Paul HudsonChief Executive Officer, Executive Director, Member of the Executive Committee, since 2019€3.8m
- Mr. Francois-Xavier RogerChief Financial Officer, Executive Vice President, Member of the Executive Committee
- Ms. Natalie BickfordChief People Officer, Executive Vice President, Member of the Executive Committee
- Mr. Roy PapatheodorouExecutive Vice President, General Counsel, Member of the Executive Committee
- Prof. Dr. Houman AshrafianExecutive Vice President, Head of Research and Development, Member of the Executive Committee
- Mr. Olivier CharmeilExecutive Vice President - General Medicines, Member of the Executive Committee
- Ms. Audrey DerveloyExecutive Vice President - Corporate Affairs, Member of the Executive Committee
- Mr. Brian FoardExecutive Vice President - Specialty Care, Member of the Executive Committee
- Mr. Emmanuel FrenehardExecutive Vice President, Chief Digital Officer, Member of the Executive Committee
- Mr. Brendan O' CallaghanExecutive Vice President - Global Manufacturing and Supply, Member of the Executive Committee
- Ms. Madeleine RoachExecutive Vice President - Business Operations, Member of the Executive Committee
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 85
- Environment
- 90
- Social
- 88
- Governance
- 75
- Direct emissions (scope 1)
- 298,485 t
- Energy emissions (scope 2)
- 318,252 t
- Value chain emissions (scope 3)
- 3,822,627 t
- Women in the workforce
- 49.6%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sanofi SA has a strong global presence with operations in multiple countries, providing a broad customer base and diversification.
- The company has a robust portfolio of products across various therapeutic areas, including pharmaceuticals, vaccines, and consumer healthcare.
- Sanofi SA invests heavily in research and development, ensuring the continuous development of innovative drugs and treatments.
Weaknesses
- Sanofi SA faces challenges in patent expirations and generic competition, impacting its market share and revenue.
- The company has a high dependence on a few key products, posing a risk if any of those products face regulatory issues or fail to meet market expectations.
- Sanofi SA's operations in emerging markets are vulnerable to regulatory and political risks, affecting its growth potential in those regions.
Opportunities
- Increasing healthcare spending globally presents opportunities for Sanofi SA to expand its market presence and reach a larger customer base.
- The growing demand for personalized medicine and advancements in technology offer possibilities for Sanofi SA to develop targeted therapies and innovative treatment approaches.
- Strategic collaborations and partnerships can help Sanofi SA to access new markets, leverage expertise, and drive business growth.
Threats
- Sanofi SA faces intense competition from other pharmaceutical companies, leading to price pressures and potential loss of market share.
- Regulatory complexities and increasing scrutiny on drug pricing and access may impact Sanofi SA's profitability and market position.
- Economic uncertainties and geopolitical factors can adversely affect Sanofi SA's global operations and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.